Suppr超能文献

肝移植后移植物功能障碍患者的分子吸附循环系统与血浆置换的比较。

Comparison of the molecular adsorbent recirculating system and plasmapheresis for patients with graft dysfunction after liver transplantation.

作者信息

Lee J Y, Kim S B, Chang J W, Park S-K, Kwon S-W, Song K W, Hwang S, Lee S G

机构信息

Department of Internal Medicine, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea.

出版信息

Transplant Proc. 2010 Sep;42(7):2625-30. doi: 10.1016/j.transproceed.2010.04.070.

Abstract

BACKGROUND

Graft dysfunction after liver transplantation (OLT) is a life- threatening condition. Molecular adsorbent recirculating system (MARS) or plasmapheresis (PLP) may be effective supportive therapy of graft dysfunction for patients who cannot undergo retransplantation. The aim of this study was to compare the effects of MARS and PLP in patients with graft dysfunction after OLT.

METHODS

Between January 2002 and July 2007, 31 OLT recipients who experienced graft dysfunction, defined as hyperbilirubinemia (>10 mg/dL) without bile duct obstruction and/or presence of hepatic encephalopathy, were treated with MARS or PLP. Biochemical and hemodynamic data and survival were compared in MARS and PLP groups.

RESULTS

Fifteen patients were treated with 41 MARS sessions and 16 with 105 PLP sessions. After a single MARS session, patients showed significant reductions in creatinine, urea nitrogen, bilirubin, and ammonia. After a single PLP session, patients showed significant improvements in prothrombin time, bilirubin, alanine aminotransferase, alkaline phosphatase, and albumin. After the completion of treatment, Both MARS and PLP significantly improved bilirubin values. at 90 days there were no differences in overall survival rates; 53% in MARS versus 56% in PLP.

CONCLUSION

Both MARS and PLP are alternative supportive treatments for graft dysfunction after OLT.

摘要

背景

肝移植(OLT)后移植物功能障碍是一种危及生命的状况。分子吸附再循环系统(MARS)或血浆置换(PLP)可能是无法接受再次移植的移植物功能障碍患者的有效支持性治疗方法。本研究的目的是比较MARS和PLP对OLT后移植物功能障碍患者的疗效。

方法

在2002年1月至2007年7月期间,31例经历移植物功能障碍(定义为无胆管梗阻的高胆红素血症(>10mg/dL)和/或存在肝性脑病)的OLT受者接受了MARS或PLP治疗。比较了MARS组和PLP组的生化和血流动力学数据及生存率。

结果

15例患者接受了41次MARS治疗,16例接受了105次PLP治疗。单次MARS治疗后,患者的肌酐、尿素氮、胆红素和氨水平显著降低。单次PLP治疗后,患者的凝血酶原时间、胆红素、丙氨酸转氨酶、碱性磷酸酶和白蛋白水平显著改善。治疗结束后,MARS和PLP均显著改善了胆红素值。90天时总体生存率无差异;MARS组为53%,PLP组为56%。

结论

MARS和PLP都是OLT后移植物功能障碍的替代支持性治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验